Iovance Biotherapeutics

IOVA

Market cap $1.57B

Iovance Biotherapeutics' most important product is generating rapidly growing sales. Between approvals in other countries and label expansions, it could maintain its momentum for a while.

Iovance Biotherapeutics is positioned for multi-year growth, with Amtagvi sales and pipeline momentum accelerating despite recent share price volatility. Real-world Amtagvi data shows a 44% ORR and 73% disease control, outperforming pivotal trial results and driving increased physician adoption in less heavily pretreated patients. IOVA's pipeline catalysts include pivotal NSCLC data in 2024, sarcoma expansion with efficient trial design, and global regulatory reviews, supporting a blockbuster potential beyond melanoma.

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?

SAN CARLOS, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on March 19, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 3,400 shares of Iovance's common stock to one new, non-executive employee.

Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often take a niche approach, developing medicines aiming to address a specific type of cancer with particular dedicated mechanisms.

Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) stock is trading higher on Friday, with no news to justify the movement.

Iovance Biotherapeutics' most important product has strong momentum right now. However, the company faces significant challenges that make the stock risky.

Iovance Biotherapeutics (IOVA) remains a high-risk, high-reward play, with lifileucel (Amtagvi) now approved for advanced melanoma and 2025 company revenues of $264m. IOVA faces persistent losses, a precarious cash runway, and intense competition, but real-world efficacy and expanding treatment center networks support cautious optimism. Key 2026–2027 catalysts include potential approvals in NSCLC and first-line melanoma, with blockbuster ambitions hinging on successful clinical and regulatory milestones.

SAN CARLOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences: